Company news

VYNE Therapeutics Inc. news in 2022

VYNE Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.

View company

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

December 6, 2022

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

November 16, 2022

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

August 11, 2022

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

August 9, 2022

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

June 16, 2022

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

May 9, 2022

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

April 6, 2022

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

March 29, 2022

VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

March 16, 2022

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

March 6, 2022

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

January 18, 2022

VYNE Therapeutics Divests Topical Minocycline Assets

January 12, 2022

Decks in 2022